The PLGA nanoparticles for sustainable release of CGRP to ameliorate the inflammatory and vascular disorders in the lung of CGRP-deficient rats

The calcitonin gene-related peptide (CGRP) has been demonstrated relating to vascular and inflammatory regulations not only the nerve systems. As the anti-inflammation factor and the most potent vasodilator, the CGRP holds therapeutic potentials for the treatment of cardiovascular diseases which was...

Full description

Saved in:
Bibliographic Details
Main Authors: Fang Wang (Author), Yu Deng (Author), Jieting Wang (Author), Luying Yu (Author), Fadian Ding (Author), Wei Lian (Author), Qicai Liu (Author), Xinhua Lin (Author)
Format: Book
Published: Taylor & Francis Group, 2021-01-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_401a97ce6a814b6491d02bee6fc3a41f
042 |a dc 
100 1 0 |a Fang Wang  |e author 
700 1 0 |a Yu Deng  |e author 
700 1 0 |a Jieting Wang  |e author 
700 1 0 |a Luying Yu  |e author 
700 1 0 |a Fadian Ding  |e author 
700 1 0 |a Wei Lian  |e author 
700 1 0 |a Qicai Liu  |e author 
700 1 0 |a Xinhua Lin  |e author 
245 0 0 |a The PLGA nanoparticles for sustainable release of CGRP to ameliorate the inflammatory and vascular disorders in the lung of CGRP-deficient rats 
260 |b Taylor & Francis Group,   |c 2021-01-01T00:00:00Z. 
500 |a 1071-7544 
500 |a 1521-0464 
500 |a 10.1080/10717544.2021.1902021 
520 |a The calcitonin gene-related peptide (CGRP) has been demonstrated relating to vascular and inflammatory regulations not only the nerve systems. As the anti-inflammation factor and the most potent vasodilator, the CGRP holds therapeutic potentials for the treatment of cardiovascular diseases which was, however, limited by its peptide nature and short half-life. With advantages in improving the stability, circulation time and protection from degradation, the nanoparticles were promising as delivery carriers for the peptide. Nevertheless, few nanoparticulate systems were developed to deliver the CGRP peptide for the modulation of vascular or inflammatory functions instead of neural regulation. In this study, the CGRP was encapsulated into the poly (lactic-co-glycolic acid) (PLGA) nanoparticle for sustained release of CGRP in vivo. The nanoparticles recovered the systemic level of CGRP and the vascular inflammatory factors in the CGRP+/− rats comparing to the administration of (Dulbecco's Phosphate Buffered Saline) DPBS or peptide only. With the decrease of vascular wall thickness and the attenuation of the T cell infiltration in the lung, the polymer based CGRP delivery system showed potentials to facilitate the therapeutic effects of the CGRP which may help for the development of CGRP-based therapy in vascular and inflammatory disorder related diseases. 
546 |a EN 
690 |a cgrp 
690 |a sustainable release 
690 |a nanoparticles 
690 |a plga delivery 
690 |a inflammatory and vascular disorders 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Drug Delivery, Vol 28, Iss 1, Pp 865-872 (2021) 
787 0 |n http://dx.doi.org/10.1080/10717544.2021.1902021 
787 0 |n https://doaj.org/toc/1071-7544 
787 0 |n https://doaj.org/toc/1521-0464 
856 4 1 |u https://doaj.org/article/401a97ce6a814b6491d02bee6fc3a41f  |z Connect to this object online.